PrimoCure Pharma’s KoDiscovery Anticancer Therapeutics - KAT 3-BP

​

PrimoCure Pharma has overcome the many challenges related to harnessing 3-BP as an anticancer therapy and has developed its KAT 3-BP solution.

KAT 3-BP is a patented formulation of 3-BP, that when combined with its proprietary administration protocols, has shown very promising preclinical results for treating pancreatic cancer with the potential of reducing tumor size and the metastatic spread of cancer cells.  

​

How It Works

​

The KAT 3-BP formulation is administered to the patient and is carried to the cancer cells.

Within the cancer cells are mono-carboxylate transporters (MCTs), which are overexpressed in many cancer cells. These MCTs transport the KAT 3-BP formulation across the membrane of the cancer cell and into its nucleus.

​

Once KAT 3-BP penetrates the cancer cell's membrane and nucleus the formulation triggers multiple irreversible reactions with different cysteine residues of proteins, leading to loss of tertiary structure and function which causes the death of the cancer cell.

Specifically, KAT 3-BP irreversibly alkylates the glycolytic enzyme, Hexokinase II (HK2), resulting in the disruption of glucose metabolism leading to cancer cell death.

​

Advantages of KAT 3-BP

​

• Due to its small molecular and chemical structure, the mechanism of action is well understood as evidenced by third parties studies. 

• Due to KAT’s mechanism of action, it can potentially target up to 95% of solid and liquid cancer types.

• Multiple studies have demonstrated that KAT 3-BP can preferentially and effectively kill cancer stem cells, which can reduce, and possibly prevent the metastatic spread of existing cancers.

• It is not only a metabolism-based therapy but is also an immunotherapy which can activate and help white blood cells to enhance immunological responses.

• The method of entry into the cell minimizes cytotoxicity to normal cells and can be used in vivo.

• It can be combined with existing standard-of-care therapies such as surgeries, immunotherapies, radiotherapies, and chemotherapies.

• It is non-mutagenic

• It does not induce drug resistance as 3BP is not a substrate for multidrug resistance (MDR) proteins

• It can be effectively delivered through multiple routes of administration according to the cancer type and individual patient need.

• It can be combined with alternative therapies such as oxygen therapy, heat therapy, traditional acupuncture and others.

​

To understand the full scope and potential of PrimoCure Pharma, Inc., as well as the vast potential for KAT 3-BP as a therapeutic drug for pancreatic and the majority of other cancers, it is necessary to take a step back to understand the roots of our heritage. First and foremost, PrimoCure Pharma is the sister closed corporation to Dr. Ko's first company, KoDiscovery, LLC, which was established as her research laboratory. Her groundbreaking discovery in 2000 of the unmatched potential 3-BP to rapidly kill cancer cells was followed by years of her painstaking research and development to carefully determine the optimum formulation, dosage, protocols and routes of administration that are safe and effective for human and animal use. Additionally, she has now successfully received numerous worldwide patents for KAT 3-BP to treat multiple cancers using multiple routes of administration, to potentially treat up to 95% of all cancers. 

​

​​

​

​

Below you may follow brief summaries of Dr. Ko's progress from her preclinical studies, animal and human case studies, the start of her first clinical trial and current plans through PrimoCure Pharma. You will also have access to many published studies validating her research and discoveries. Through this progression you will come to more fully understand the strengths of Dr. Ko's KAT 3-BP formulation and the vast potential it promises for the treatment of the majority of cancers across the globe.